The first study to evaluate outcomes of fully vaccinated cancer patients with breakthrough COVID-19 infections indicates they are at high risk for hospitalization and death. The study also appears to support previous observations that patients with hematologic malignancies are at greater risk for severe outcomes from the disease. Patients on a treatment regimen of corticosteroids also appeared to be more susceptible to hospitalization.
The study, published Dec. 24 in Annals of Oncology showed that such patients had a hospitalization rate of 65%, an ICU or mechanical ventilation rate of 19%, and a 13% death rate. The study was conducted by the COVID-19 and Cancer Consortium (CCC19), a group of 129 research centers that has been tracking the impact of COVID-19 on patients with cancer since the beginning of the pandemic.
“Patients with cancer who develop breakthrough COVID-19 even following full vaccination can still experience severe outcomes, including death,” said Toni Choueiri, MD, director of the Lank Center for Genitourinary Care at Dana-Farber Cancer Institute and a senior author on the report. “That is why a multilayered approach that includes masking and social-distancing, along with vaccination plus booster against COVID-19 remains an essential approach for the foreseeable future.”
Patients were considered fully vaccinated after having received two doses of either the BioNTech, Pfizer vaccine or the Moderna, NIAD vaccine, or one dose of the J&J vaccine, with the last vaccine dose long enough before breakthrough COVID-19, to consider them as fully vaccinated. The data were collected between Nov. 1, 2020, and May 31, 2021, before booster vaccines were recommended for patients with cancer by the U.S. Centers for Disease Control and Prevention.
“Because measures of immunity are not routinely collected in clinical care, we don’t know whether these were patients who mounted effective immune responses after vaccination; a lot of emerging data have suggested that patients with cancer, especially blood cancers, don’t mount adequate protective antibody responses,” said Jeremy Warner, MD, director of the CCC19 Research Coordinating Center, associate professor at Vanderbilt-Ingram Cancer Center and a senior author of the study.
He added, “It’s important to note that many of the same factors that we identified prior to the availability of vaccination – age, comorbidities, performance status, and progressing cancer – still seem to drive many of the bad outcomes.”
The consortium identified 1,787 patients with cancer and COVID-19 for the study, the vast majority of which were unvaccinated. The number of fully vaccinated was 54, and 46% of those fully vaccinated had reduced levels of lymphocytes — the T cells and B cells responsible for immunological responses to viruses. Lymphopenia commonly occurs in patients with cancer receiving anti-CD20 monoclonal antibodies or CAR-T-cell treatments for hematologic malignancies, including lymphoma and leukemia.
“Similar results (high mortality rates among fully vaccinated individuals) have been reported in other immunocompromised patient populations, such as organ transplant recipients, prior to the utilization of additional vaccine doses,” said Dimitrios Farmakiotis, MD, an infectious disease clinician at the Warren Alpert Medical School of Brown University and a senior author of the study.
He added that, “These findings come at a time of concerns that immune escape mutants such as the omicron strain may emerge from chronically infected patients with weakened immune systems. Thus, the immunosuppressed and their close contacts should be target groups for therapeutic and preventive interventions, including community-level outreach and educational efforts.”
